Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. develops and markets orthopaedic medical devices for the surgical treatment of bunions and related midfoot deformities. Its updates center on the Lapiplasty® 3D Bunion Correction procedure and related technologies used by surgeons, ambulatory surgery centers and hospitals.
Recurring news themes for TMCI include quarterly and annual financial results, revenue guidance, surgeon adoption, cash and liquidity updates, product introductions and clinical data. Company announcements also cover additions to the bunion and midfoot technology portfolio, including SuperBite™ Compression Screw System, Lapiplasty® Lightning™ technology, SpeedMTP® and IntelliGuide® PSI, as well as patent portfolio activity and presentations at foot and ankle surgery conferences.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company specializing in bunion treatment, reported Q2 2025 financial results with revenue of $47.4 million, up 7% year-over-year. The company reduced its net loss by 18% to $(17.4) million and improved adjusted EBITDA by 58% to $(3.6) million.
Key developments include the full market release of three new bunion technologies: Nanoplasty®, Percuplasty™, and SpeedMTP® systems. The company's Align3D™ technology received validation through four-year clinical data publication. Treace maintains its 2025 revenue guidance of $224-230 million, projecting 7-10% growth, and expects to achieve breakeven Adjusted EBITDA for full-year 2025.
The company's financial position includes $90.7 million in total liquidity, with cash usage decreasing by 55% in Q2 2025 compared to the prior year.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company focused on bunion and midfoot deformity treatments, will host an Investor Day on September 3, 2025, at 9:00 am ET in New York.
The event will feature presentations from management and experienced surgeons who will share their experiences with the company's expanded technology portfolio. Interested investors can register through investor relations by August 27, 2025. A live webcast and replay will be available on the company's investor relations website.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company specializing in bunion surgery solutions, has published four-year interim results from its ALIGN3D™ multicenter prospective study in the Journal of Foot & Ankle Surgery. The study, which followed 139 of 173 patients, demonstrated strong outcomes for the Lapiplasty® Procedure.
Key findings include an early return to protected weight bearing at 7.7 days, transition to athletic shoes at 6.5 weeks, and notably low recurrence rates of 0.8% using HVA>20° and 8.4% using HVA>15° at 48 months. Patient outcomes showed significant improvements, with an 81% reduction in pain and 89% improvement in walking/standing capabilities through the 48-month period.
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company specializing in surgical treatments for bunions through its Lapiplasty® and Adductoplasty® Procedures, has scheduled its Q2 2025 earnings release for August 7, 2025 after market close.
The company will host a conference call at 4:30 PM ET to discuss the results. Investors can participate by registering to receive dial-in information. A webcast will be available on the company's investor relations website.
Treace Medical Concepts (NASDAQ: TMCI) reported its Q1 2025 financial results, showing revenue of $52.6 million, a 3% increase year-over-year. The company improved its net loss by 15% to $(15.9) million compared to $(18.7) million in Q1 2024. Adjusted EBITDA improved 53% to $(3.8) million from $(8.2) million in the same period.
The company expanded its bunion technology portfolio through limited releases of Nanoplasty™, Percuplasty™ 3D MIS Osteotomy Systems, and SpeedMTP™ MTP Fusion System. Treace maintained a strong gross margin of 79.7% and ended the quarter with total liquidity of $98.6 million. The company reaffirmed its full-year 2025 revenue guidance of $224-230 million, representing 7-10% growth, and expects to reach breakeven Adjusted EBITDA for 2025.
Treace Medical Concepts (TMCI), a medical technology company specializing in bunion and midfoot deformity surgical treatments through its Lapiplasty® and Adductoplasty® Procedures, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 pm ET to discuss the results. Interested investors can participate by registering to receive dial-in numbers and a unique pin. A live and archived webcast will be available on the company's investor relations website at https://investors.treace.com/.
Treace Medical Concepts (NASDAQ: TMCI) announced a significant leadership transition as CEO and Founder John T. Treace will assume the role of Chairman of the Board following the 2025 annual stockholders meeting on May 20, 2025. He will succeed James T. Treace, who will retire from the Board after serving as Chair since the company's inception in 2014.
John T. Treace will maintain his position as CEO while taking on the Chairman role. Richard W. Mott will continue serving as lead independent director. The company, known for its Lapiplasty® and Adductoplasty® Procedures in bunion treatment, expressed commitment to delivering additional innovations and expanding its bunion portfolio to drive market penetration throughout 2025 and beyond.
Treace Medical Concepts (NASDAQ: TMCI) presented updated clinical data for its bunion and midfoot deformity treatments at the 2025 ACFAS Conference. The company showcased results from three key studies:
The ALIGN3D™ study (135 patients, 4-year follow-up) showed early weight bearing at 8.4 days and low recurrence rates of 0.8% 20°). The Mini3D™ study (75 patients, 1-year follow-up) demonstrated weight bearing at 7.9 days with 0% recurrence 20°). The MTA3D™ study (18 patients, 1-year follow-up) reported weight bearing at 7.5 days with significant improvements in both midfoot and bunion deformity correction.
All studies showed significant improvements in pain and patient-reported outcomes. Additional retrospective data from 43 patients undergoing Adductoplasty® and Lapiplasty® procedures showed positive clinical results over a 17.7-month follow-up period.
Treace Medical Concepts (TMCI) announced new technological innovations to be showcased at the 2025 ACFAS Annual Scientific Conference in Phoenix, Arizona. The company introduced several advancements in their bunion treatment portfolio, including:
- Micro-Lapiplasty™ and Mini-Adductoplasty™ platforms with SpeedPlate™ MicroQuad™ implant for small incision approaches
- Two new 3D minimally invasive systems: Nanoplasty™ and Percuplasty™, complemented by SpeedAkin™ implant
- SpeedMTP™, combining SpeedPlate™ compression fixation with Fastpitch™ locking screws for arthritic great toe joint treatment
- IntelliGuide™ PSI cut guides, offering pre-op planning, patient-specific 3D-printed guides, and Bone Clone™ anatomic foot models